PUBLISHER: The Business Research Company | PRODUCT CODE: 2133596
PUBLISHER: The Business Research Company | PRODUCT CODE: 2133596
Digital therapeutics (DTx) are products that deliver evidence-based therapeutic interventions to patients through high-quality software applications to prevent, manage, or treat medical conditions or diseases.
The primary product types of digital therapeutics include devices and software. Digital therapeutics devices deliver interventions designed to prevent, manage, or treat diseases and medical disorders. These include devices such as sensors that monitor medication usage and location data. The different sales channels comprise business-to-business (B2B) and business-to-consumer (B2C). Digital therapeutics are utilized for preventive applications as well as treatment and care-related applications.
Tariffs are influencing the digital therapeutics market by increasing the costs of imported wearable components, biosensors, electronic modules, and supporting hardware devices. Healthcare providers and technology companies in North America and Europe are most affected due to their dependence on imported electronics, while Asia-Pacific is experiencing cost pressures in device manufacturing. These tariffs are increasing development and deployment expenses. However, they are also encouraging local device assembly, regional software innovation, and a greater focus on scalable, software-centric therapeutic solutions.
The digital therapeutics market research report is one of a series of new reports from The Business Research Company that provides digital therapeutics market statistics, including digital therapeutics industry global market size, regional shares, competitors with a digital therapeutics market share, detailed digital therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the digital therapeutics industry. This digital therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The digital therapeutics market size has grown exponentially in recent years. It will grow from $10.96 billion in 2025 to $14.11 billion in 2026 at a compound annual growth rate (CAGR) of 28.8%. The growth during the historic period can be attributed to increasing smartphone penetration in healthcare, growing acceptance of digital health solutions, expansion of telemedicine services, early regulatory approvals for digital therapeutics, and the rising burden of chronic diseases.
The digital therapeutics market size is expected to see exponential growth in the next few years. It will grow to $38.19 billion in 2030 at a compound annual growth rate (CAGR) of 28.3%. The growth during the forecast period can be attributed to increasing reimbursement support for digital therapeutics, rising demand for personalized digital care, expansion of AI-driven treatment platforms, growing partnerships between healthcare providers and technology firms, and increasing emphasis on preventive digital health. Major trends in the forecast period include increasing adoption of software-based therapeutic solutions, greater integration of wearable health devices, growing use of remote patient monitoring platforms, expansion of evidence-based digital care programs, and enhanced focus on personalized treatment pathways.
The growing prevalence of chronic diseases is expected to support the growth of the digital therapeutics market going forward. Chronic diseases are long-term conditions that generally persist for one year or longer and require continuous medical care or restrict daily activities, or both. Digital therapeutics are software-based interventions that provide evidence-based therapeutic treatments to patients, supporting chronic disease management and expanding available treatment options. For instance, in March 2025, according to the Office for Health Improvement & Disparities (OHID), a UK-based unit of the Department of Health and Social Care, the GP-recorded prevalence of type 2 diabetes among adults aged 17 and over in England was 7.0% in March 2024, up from 6.8% in March 2023. Therefore, the growing prevalence of chronic diseases is driving the growth of the digital therapeutics market.
Major companies operating in the digital therapeutics market are concentrating on technological advancements such as prescription-only digital behavioral therapy platforms to increase treatment accessibility, strengthen patient engagement, and deliver clinically validated outcomes. A prescription-only digital behavioral therapy platform uses software-based interventions delivered through smartphones or tablets, incorporating evidence-based modules such as cognitive behavioral therapy (CBT), remote monitoring, and interactive goal tracking. These platforms enable scalable, drug-free disease management while providing personalized patient support. For instance, in July 2023, Better Therapeutics, a US-based prescription digital therapeutics company, launched AspyreRx (formerly BT-001), a digital therapeutic designed for type 2 diabetes. The product provides a 90-day self-paced program through a smartphone application, incorporating weekly CBT lessons, personalized goal-setting, and tracking of blood glucose and lifestyle data; clinical trials showed sustained reductions in HbA1c, improvements in weight, and enhanced quality-of-life outcomes.
In July 2023, Big Health, a US-based provider of digital therapeutics, acquired Limbix for an undisclosed amount. The acquisition is expected to expand Big Health's existing product portfolio, which includes Sleepio for insomnia and Daylight for anxiety, by adding Limbix's SparkRx and another teenage medication in development for anxiety. Limbix is a US-based provider of digital therapeutics.
Major companies operating in the digital therapeutics market are Omada Health Inc., WellDoc Inc., 2Morrow Inc., Propeller Health, Pear Therapeutics, Canary Health Inc., Noom Health Inc., Akili Interactive Labs, Better Therapeutics, Happify Health, Kaia Health, Medtronic plc, Teladoc Health Inc., Fitbit Health Solutions, EMulate Therapeutics, BigHealth, DarioHealth, IQVIA, JOGO Health, SilverCloud Health, Biofourmis Inc., Prosoma, Virta Health Corp., One Drop Inc., Lark Health, Xealth, CogniFit Ltd.
North America was the largest region in the digital therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the digital therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The digital therapeutics market consists of sales of products to treat a disease, manage a condition, and improve a health function. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Digital Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses digital therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for digital therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The digital therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.